Balancing Quality of Care and Costs in Urology Practices


Balancing costs while preserving access to high quality care is an important topic in cancer care. The recent explosion of new therapies for patients with urologic cancer has brought this issue to the forefront of conversation, particularly in advanced prostate cancer.

E. David Crawford, MD, and Mark S. Austenfeld, MD, believe this issue will continue to be discussed, as better medications and devices become available and costs continue to rise. Additionally, Crawford believes it may be best to combine these therapies, which would further increase the cost per treatment course. With multiple new drug approvals in the last few years extra costs are inevitable, Neal D. Shore, MD, notes. These extra costs are primarily tied to the high price of research and development for new drugs.

Ultimately, the panel agrees that physicians should remain conscious of costs while offering the best care to patients.

Related Videos
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Samer A. Srour, MB ChB, MS
Scott T. Tagawa, MD, MS, FACP, FASCO
Carmen Guerra, MD, MSCE, FACP
Kara N. Maxwell, MD, PhD
Josep Maria Piulats Rodriguez, MD, PhD
Samer A. Srour, MB ChB, MS
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
Phillip J. Koo, MD